284463-59-8

Upstream product

• 326-90-9 4,4,4-trifluoro-1-(2-furanyl)-1,3-butanedione 
• 2237-30-1 m-cyanoaniline 
• 17672-26-3 3-cyanophenyl hydrazine 
• 557-21-1 dicyanozinc 
• 284463-58-7 1-(3-chloro-phenyl)-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole 

Downstream Products

• 209917-93-1 1-(3-cyanophenyl)-3-trifluoromethylpyrazole-5-carboxylic acid 

Relevant academic research and scientific papers

Palladium-catalyzed cyanation reactions of aryl chlorides

We have discovered an efficient cyanation of aryl chlorides which employs Pd2(dba)3, dppf and Zn as the catalyst and Zn(CN)2 as the cyanide source. Both electron-deficient and electron-rich aryl chlorides are effectively cyanated under these conditions. This discovery represents the first successful palladium-catalyzed cyanation of both electron-deficient and electron-rich aryl chlorides. (C) 2000 DuPont Pharmaceuticals Company.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

AMIDINOANILINE DERIVATIVE

Provided are a novel amidine derivative having an activated blood coagulation factor X inhibitory activity, a production method thereof, a production intermediate therefor, and a pharmaceutical composition containing the amidine derivative. An amidinoanil

SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS)

The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. Said compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.